Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window

 With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st July, 2019 till 48 hours after the declaration of the unaudited financial results for the quarter ended 30th June, 2019. The date of the Board Meeting for considering the unaudited financial results for the quarter ended 30th June, 2019, will be intimated in due course. We request you to kindly take the same on record.
28-06-2019
Bigul

Alembic Pharma gets USFDA nod for influenza infection capsules

 Drug firm Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator for Oseltamivir Phosphate capsules, used for
25-06-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base) and 75 mg (base). Please find enclosed herewith our press release. We request you to kindly take the same on record.
25-06-2019
Bigul

Alembic Pharma gets USFDA nod for ophthalmic solution

 Drug firm Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator for Bromfenac Ophthalmic Solution, used for t
24-06-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Bromfenac Ophthalmic Solution 0.09%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
24-06-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s).
20-06-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal hier(s) of the registered shareholders on 18th June, 2019.
18-06-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice w.r.t. transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) published in English and vernacular language (Gujarati) newspaper on 18th June, 2019 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record.
18-06-2019
Bigul

Company news: Alembic Pharmaceuticals

 The board of directors of Alembic Pharmaceuticals on Wednesday approved the issue of unsecured, listed, rated, redeemable, non-convertible debentures
12-06-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Outcome of Board Meeting

 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter-alia (i) approved the Issue of Unsecured Listed Rated Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 300 Crores on Private Placement Basis under a shelf disclosure document in one or more tranches and (ii) Constituted NCD Committee for issue and allotment of NCDs. The time of commencement of the Board Meeting was 11:00 a.m. and the time of conclusion was 11:45 a.m.
12-06-2019
Next Page
Close

Let's Open Free Demat Account